Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01064518 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
A Phase 2 study, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT01064518 is a Phase 2 study that has completed, run by Revance Therapeutics. The registered enrollment target is 90 participants.
The verdict
NCT01064518, a Phase 2 study, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if an investigational drug, called RT001 Botulinum Toxin Type A Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called crow's feet, also known as lateral canthal lines.
Interventions
- DRUG Botulinum Toxin Type A
- DRUG Placebo (Dose B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01064518
The ClinicalTrials.gov registry entry for NCT01064518 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Botulinum Toxin Type A is the first listed.
NCT01064518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01064518 about?
NCT01064518 is a clinical study titled "Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults". The purpose of this study is to find out if an investigational drug, called RT001 Botulinum Toxin Type A Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called crow's feet, also known as lateral canthal lines.
What is the current status of trial NCT01064518?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2010-01. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01064518?
The interventions under investigation include: Botulinum Toxin Type A (DRUG), Placebo (Dose B) (DRUG).
Who is sponsoring clinical trial NCT01064518?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.